Breakdown | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 768.50M | 661.54M | 633.67M | 683.03M | 783.03M |
Gross Profit | 112.69M | 98.25M | 127.92M | 180.42M | 291.38M |
EBITDA | -1.20B | -1.33B | -1.17B | -718.52M | -672.89M |
Net Income | -1.28B | -1.44B | -1.25B | -843.39M | -842.01M |
Balance Sheet | |||||
Total Assets | 5.70B | 5.63B | 6.08B | 5.38B | 5.25B |
Cash, Cash Equivalents and Short-Term Investments | 4.65B | 4.40B | 4.50B | 4.10B | 3.64B |
Total Debt | 781.00K | 2.31M | 4.30M | 7.69M | 16.46M |
Total Liabilities | 509.27M | 590.20M | 566.14M | 474.95M | 442.99M |
Stockholders Equity | 5.19B | 5.04B | 5.51B | 4.90B | 4.81B |
Cash Flow | |||||
Free Cash Flow | -1.33B | -1.35B | -1.20B | -1.01B | -653.01M |
Operating Cash Flow | -1.27B | -1.26B | -1.16B | -974.70M | -632.92M |
Investing Cash Flow | 65.14M | 3.27M | -20.23M | 344.25M | 86.20M |
Financing Cash Flow | 1.46B | 1.16B | 1.58B | 1.08B | 2.79B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
65 Neutral | ¥355.44B | 11.10 | -2.99% | 2.49% | 11.76% | -10.16% | |
59 Neutral | ¥10.32B | ― | ― | 8.68% | 13.81% | ||
55 Neutral | ¥14.01B | ― | ― | 109.03% | 98.53% | ||
48 Neutral | ¥15.43B | ― | ― | 11.93% | 15.04% | ||
41 Neutral | ¥7.53B | ― | ― | -97.61% | 14.80% | ||
40 Underperform | ¥9.68B | ― | -26.97% | ― | -30.46% | 39.41% |
MEDINET Co., Ltd. reported a decrease in net sales by 17.7% for the first quarter ending December 2024, with a net loss of 345 million yen, indicating financial challenges. Despite a high capital adequacy ratio of 91%, the company did not declare any dividends, highlighting a cautious financial approach amidst declining profits.